A Placebo-Controlled, Double-Blind, Randomized, Single Dose, Dose Escalating Trial in Healthy Men to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPC3649
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2009
At a glance
- Drugs Miravirsen (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Santaris Pharma
- 23 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 09 Jan 2009 Planned end date changed from 1 Nov 2008 to 1 Mar 2009 as reported by ClinicalTrials.gov.